P1177: PROGNOSTIC VALUE OF TP53 VARIANTS IN CHILDREN WITH MATURE B-CELL LYMPHOMA TREATED ACCORDING TO REDUCED-INTENSITY B-NHL-2010M PROTOCOL
Main Authors: | V. Egor, A. Yuliya, K. Brenning, A. Itov, D. Abramov, A. Sharlai, M. Senchenko, D. Konovalov, G. Novichkova, N. Miakova |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847572.01183.fa |
Similar Items
-
Combined chemoimmunotherapy of patients with mature B-cell non-Hodgkin lymphomas age group until 18 years: results of multicenter study NHL 2004 m with rituximab and modified B-NHL BFM 90 protocol applications
by: E. V. Samochatova, et al.
Published: (2022-11-01) -
PB2154: TP53 GENE MUTATION DIVERSITY IN RUSSIAN PATIENTS WITH B-CELL LYMPHOMAS
by: B. Biderman, et al.
Published: (2022-06-01) -
CLINICAL SIGNIFICANCE OF THE TP53 MUTATION STATUS IN DIFFUSE LARGE B-CELL LYMPHOMA
by: E. N. Voropaeva, et al.
Published: (2019-03-01) -
Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy
by: Yang Li, et al.
Published: (2023-11-01) -
Retraction to 10.1177/1758835920922055
Published: (2023-04-01)